ライフサイエンスコーパス: dose-related

1 se events were not life threatening and were dose related.

2 neutropenia (<1,500/mm3), both of which were dose related.

3 Adverse events tended to be minor and not dose related.

4 AEs were common and appeared to be dose related.

5 ns speculative, its occurrence appears to be dose related.

6 gallate levels did not accumulate nor appear dose related.

7 llele, cardiomyopathy was infrequent and not dose related.

8 rcalcemia and hypercalciuria, which were not dose related.

9 otype, cardiomyopathy was infrequent and not dose related.

10 , fatigue, nausea, and diarrhea and were not dose related.

11 The effects were transient and not dose-related.

12 was the major dose-limiting toxicity and was dose-related.

13 olone methyl groups, were generally mild and dose-related.

14 ), which were single elevations and were not dose-related.

15 ry (DILI) is traditionally thought not to be dose-related.

16 3 hours postinjection and whose strength was dose-related.

17 and the magnitude of severity reduction was dose-related.

18 g of renal function, nausea, vomiting), were dose-related.

19 This effect was dose-related.

20 enias also occurred in all subjects and were dose-related.

21 626 into the PFC (but not striatum) caused a dose-related (0.63-2.5 mug/side) impairment of NOR.

22 tex (PFC) of rats increased SND and caused a dose-related (0.63-2.5 mug/side) improvement in NOR, whi

23 t recipients during combination therapy were dose related (20 mg/kg, 30-182 ng/mL; 7 mg/kg, 7-41 ng/m

24 A dose-related 20S PI was seen, with dose-limiting toxicit

25 Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilo

26 5), and urinary 11-dehydrothromboxane B2 was dose-related (81 mg versus 325 mg, P = 0.003).

27 he sustained virologic response rate was not dose-related above 1.0 microg/kg peginterferon alfa-2b b

28 We now report that planarians also display dose-related abstinence-induced withdrawal following exp

29 utable to baseline increased TDR and greater dose-related accentuation of TDR compared with nonhypert

30 ood oral activity in these models, including dose-related activity in a LoVo xenograft.

31 ne compound, 9 (NVP-LAQ824), had significant dose-related activity in the HCT116 colon and A549 lung

32 rces of referral, body region scanned, type, dose, related adverse events and route of administration

33 There were no clinically significant dose-related adverse effects on vital signs, serum chemi

34 This approach leads to profound dose-related adverse effects.

35 The most common and only dose-related adverse event was diarrhea (only 6 patients

36 effects of the two dosages and the increased dose-related adverse events with the higher dosage sugge

37 asing plasma 25(OH)D concentrations, with no dose-related adverse events.

38 onship between intrathecal GBCA exposure and dose-related adverse events.

39 Dose-related AEs included hypotension (36%), vomiting (2

40 ermore, the effect does not seem to be virus-dose related, although it does require infection.

41 The effect duration was dose related and persisted longer in patients who receiv

42 Omecamtiv mecarbil infusion resulted in dose-related and concentration-related increases in syst

43 bited CD4 effector T-cell proliferation in a dose-related and donor alloAg-specific manner.

44 NSI-189 area under the curve increased in a dose-related and nearly proportional manner across the t

45 Because the toxicity of melphalan is dose-related and survival with AL may be age-related, pa

46 Toxicity is dose-related and time-related, and is due to intramyofib

47 curred in 7 patients in phase 1 (but was not dose-related) and in 4 patients in phase 2.

48 are time locked to drug administration, are dose related, and are transient and rarely necessitate i

49 festations of systemic medications are often dose related, and may reflect the potential risk for len

50 nt was nausea, which in most cases was mild, dose-related, and resolved spontaneously or after dose r

51 ed in 56 patients assigned to azimilide, was dose-related, and tended to occur earlier with an azimil

52 receptor gene, was associated with an allele dose-related antibody decrease (p = .039).

53 urpose of this study was to characterize the dose-related antidepressant effects of ketamine in patie

54 was safe and induced a profound, rapid, and dose-related antiplatelet response.

55 Statin side effects may be dose-related, associated with other drug interactions th

56 Dose-related autoimmune adverse events, predominantly sk

57 XmAb5574 infusion caused an immediate and dose-related B-cell depletion in the blood (to <10% of b

58 n from societal guidelines, imply that these dose-related benchmarks may be used to further standardi

59 Although BB therapy exerted dose-related benefits across all study participants, sST

60 These toxic effects are frequently dose related but may be enhanced by radiation therapy.

61 odarone, as measured by time to success, was dose related but not significantly for any arrhythmia su

62 In the midbrain, N(2)O caused significant dose-related c-Fos expression in the Edinger-Westphal nu

63 ancer drugs, is associated with a cumulative dose-related cardiomyopathy, the etiology of which remai

64 od chemotherapeutic agent, is limited by its dose-related cardiomyopathy.

65 of in vivo toxicology revealed a significant dose related cardiotoxicity.

66 wide range of malignancies, but it causes a dose-related cardiotoxicity that can lead to heart failu

67 in continues to be limited by its cumulative dose-related cardiotoxicity.

68 Therefore, it was important to identify the dose-related cardiovascular responses elicited by centra

69 ce lacking Wdr62, Aspm, or both showing gene dose-related centriole duplication defects that parallel

70 , binding studies did not reveal any choline-dose-related change in binding in any hippocampal region

71 Although there was a significant gene-dose-related change in hippocampal alpha7 receptor numbe

72 therapeutic dose range is associated with a dose-related change in normal brain, detectable by quant

73 With concentrations up to 3 M NaCl, the dose-related change in the hexagonal lattice constant de

74 urs after administration indicate a possible dose-related change in this pharmacodynamic marker.

75 No apparent temporal or dose-related changes in clinical status (specifically ac

76 While we did not find heroin dose-related changes in mRNA expression levels in C57 mi

77 Dose-related changes in the ONL and photoreceptor cell n

78 Dose-related changes were analyzed with generalized esti

79 normal cells there was no difference in the dose-related cytotoxicity of FVCB compared to that of FT

80 A dose-related decline in relative risk was observed with

81 receptor gene was associated with an allele dose-related decrease (P = .019) in rubella antibody res

82 polymorphism rs3790567 was associated with a dose-related decrease in IL-1beta secretion (p=0.009 for

83 shifted response choice in rats, producing a dose-related decrease in lever pressing and a concomitan

84 Our analyses also demonstrated a dose-related decrease in lung function with increasing l

85 the RIG-I gene was associated with an allele dose-related decrease in rubella antibody level from 37.

86 phatidylethanolamine, the proteins induced a dose-related decrease in the hexagonal lattice constant.

87 At 0.05 mg/kg, 8OH and APO induced similar dose related decreases (up to approximately 50%) in loco

88 Dose-related decreases in iliac vascular conductance wer

89 The combined 8OH plus APO treatment induced dose-related decreases in locomotion (approximately 90%)

90 We observed a dose-related delay in disease onset, a reduction in symp

91 Rash and dose-related deterioration of gait and balance were expe

92 Expected dose-related diarrhea and skin toxicity were observed in

93 ted in fecal colonization (100% of monkeys), dose-related diarrhea, and robust immune responses.

94 xpression levels in C57 mice, we did observe dose-related differences in 129 mice.

95 icroM) and bradykinin (1 and 10 nM) produced dose-related dilatation of the basilar artery in non-alc

96 f acetylcholine (1.0 and 10 microM) produced dose-related dilatation of the basilar artery in non-dia

97 tory effects with CXCR2 antagonism, although dose-related discontinuations were observed because of A

98 Potent dose-related DNA demethylation occurred on the daily x 5

99 Dose-related drug exposure in monkeys was established an

100 en days 2 and 5) also revealed a significant dose-related effect (saline: 12.5%, 0.2 mg/kg: 39.1%; 0.

101 tidylcholine (DOPC), the proteins produced a dose-related effect on curvature that depended on the ph

102 o 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and

103 A possible dose-related effect on residual viremia supports future

104 from either an altered immune response or a dose-related effect.

105 acebo-controlled, crossover study to examine dose-related effects of AV-101 (720 and 1440 mg) on NMDA

106 The acute, dose-related effects of Delta(9)-THC on Lempel-Ziv compl

107 ioral effects to Delta(9)-THC, there were no dose-related effects of Delta(9)-THC on P300a/b amplitud

108 The current study examined the acute, dose-related effects of delta-9-tetrahydrocannabinol (De

109 The acute, dose-related effects of Delta-9-tetrahydrocannabinol (De

110 In this follow-up investigation, we examined dose-related effects of foetal antiepileptic drug exposu

111 these hypotheses, the present study explored dose-related effects of YO on food intake, conditioned f

112 In contrast, triazolam showed dose-related effects on a wide range of subject-rated, o

113 in hemodynamic response shows characteristic dose-related effects that differ depending on agonistic

114 ntation and decreased motility, the scale of dose-related effects varied with the presence and relati

115 ied to interrogate the cells and significant dose-related effects were detected.

116 Dose-related effects were observed for tolerability, gly

117 We sought to determine the dose-related efficacy and onset of action of the HDM sub

118 m was to identify determinants of omalizumab dose-related efficacy in the context of OIT.

119 t report to our knowledge to demonstrate the dose-related efficacy of R/S-ketamine for treatment-resi

120 actory CD (CATS1) was well tolerated and had dose-related efficacy.

121 Subsequently, a dose-related erythema developed at treatment sites by 3

122 We observed significant (p </= 0.01) dose-related excess risk for male breast cancer incidenc

123 BMS-936558 exhibited dose-related exposure increases, with a half-life of 20-

124 different amounts of RV achieved stable and dose-related expression of hFIX without anti-hFIX antibo

125 censed doses of 150 mg and 300 mg, there are dose-related falls in blood pressure comparable to those

126 sing the international normalized ratio in a dose-related fashion (trend p < or = 0.0001).

127 graphic (BSE) signs of seizure activity in a dose-related fashion compared to vehicle-treated mice.

128 violet erythema was inhibited by L-NAME in a dose-related fashion with 2 mM L-NAME causing total abol

129 o reinnervation of the nucleus gracilis in a dose-related fashion, whereas NT-3 expression in the ret

130 % to 93% of patients receiving rhvCNTF, in a dose-related fashion, with mild injection site reactions

131 ncer tissue after intravenous infusion, in a dose-related fashion.

132 lar and cortical bone mineral densities in a dose-related fashion.

133 om a toxic lesion in both a time-related and dose-related fashion.

134 NMDA in mice were inhibited by thrombin in a dose-related fashion.

135 ocal (partial)-onset seizure frequency, in a dose-related fashion.

136 allenge with S. pneumoniae types 1 or 4 in a dose-related fashion; mice that received anti-pneumolysi

137 Remarkably, this same dose-related functional difference was observed with the

138 Mild dose-related gastrointestinal side effects (nausea, loos

139 The most frequent dose-related grade 1 and 2 adverse events were an acne-l

140 Dose-related grade 3 fatigue and vomiting were observed

141 phin-II (0.1-1 microg) produced an immediate dose-related hyperthermia following injection.

142 gonist, PD128,907 (0.63-40 mug/kg), caused a dose-related impairment in performance in rats in both t

143 At 12 months, there were dose-related improvements in clinical outcomes, includin

144 authors cannot exclude the possibility of a dose-related increase at the highest levels of exposure

145 macological glucokinase activator produced a dose-related increase in [Ca(2+)](i) oscillations in glu

146 In a 52-week study with liraglutide, a dose-related increase in absolute pancreas weight was ob

147 produced no evident toxicity; a significant, dose-related increase in activated partial thromboplasti

148 lpha-acetoxytamoxifen and 4-OHtamQM caused a dose-related increase in adduct levels, resulting in a d

149 By aerosol, gVPLA2 caused dose-related increase in airway resistance in saline-tre

150 We observed a dose-related increase in bleeding and a trend toward a r

151 This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evide

152 The trend for a dose-related increase in cardiovascular events and blood

153 LPS provoked a robust and dose-related increase in Fos expression within the PVH o

154 Repeated daily administration leads to a dose-related increase in gene expression.

155 inhaled corticosteroids is associated with a dose-related increase in hip fracture.

156 was significantly associated with an allele dose-related increase in IFN-gamma production and was al

157 nhanced exploratory behaviour and produced a dose-related increase in ipsilateral rotation in rats wi

158 However, there was a dose-related increase in itching, pain, edema, and stain

159 Diazepam (0.3 and 1 mg/kg) produced a dose-related increase in locomotor activity, which reach

160 In parallel experiments, ITPP caused a dose-related increase in maximal exercise capacity, with

161 eater effect in higher doses, but an inverse dose-related increase in myopia during phase 2 (washout)

162 Both stimuli produced a dose-related increase in neutrophil accumulation.

163 % confidence interval 1.5-2.0]), including a dose-related increase in risk (< or = 5 mg/day HR 1.4 [9

164 ral TRIM5 gene was associated with an allele dose-related increase in rubella antibody.

165 VNP20009 induced a dose-related increase in the circulation of proinflammat

166 Celecoxib use was associated with a dose-related increase in the composite end point of deat

167 administration of ITPP (0.5-3 g/kg) caused a dose-related increase in the oxygen tension at which Hb

168 ne was well tolerated and produced a robust, dose-related increase in treatment retention.

169 dose, lixivaptan produced a significant and dose-related increase in urine volume over 4 h, compared

170 A dose-related increase was measured in the expression of

171 Such dose-related increase was not found in studies of 4, 13,

172 There was a "dose related" increase in likelihood of having IBS with

173 atypical antipsychotic drugs had a similar, dose-related increased risk of sudden cardiac death.

174 HGNS produced marked dose-related increases in airflow without arousing patie

175 Dose-related increases in antibody responses to all 4 vi

176 Dose-related increases in antibody responses were noted

177 Active COC and AMPH produced dose-related increases in cardiovascular function that w

178 Dose-related increases in exercise duration at peak and

179 .0 mg/kg of mephedrone or methylone produces dose-related increases in extracellular dopamine and ser

180 ot in M(1) mAChR KO mice, VU0453595 produced dose-related increases in high frequency gamma power, a

181 Transient, dose-related increases in methemoglobin levels were obse

182 Dose-related increases in nasal and serum IP-10 were obs

183 Injections of arachidonic acid caused dose-related increases in pulmonary vascular resistance

184 In contrast, COC, but not AMPH, produced dose-related increases in several subjective measures of

185 icromol/kg twice a day for 3 days) exhibited dose-related increases in the cortical and striatal deme

186 There were no dose-related increases in the frequency of adverse event

187 No statistically significant dose-related increases in the geometric mean titers (GMT

188 Dose-related increases in tumoral nitroreductase express

189 administration produced significant (P<0.05) dose-related increases of c-Fos expression in several fo

190 regimen of dexmedetomidine sedation and any dose-related influence on neurophysiologic function.

191 tanserin (1, 10 and 100mug/50mul) produced a dose related inhibition of the evoked responses to noxio

192 oduction and mRNA levels showed a potent and dose-related inhibition following 3 and 4 days of treatm

193 thioTEPA was found to yield a pronounced dose-related inhibition in cell proliferation, while 5-f

194 In all cases, toxic responses (i.e. dose-related inhibition of algal motion) were detected w

195 ed calcium influx in F-11 cells and produced dose-related inhibition of capsaicin-induced flinching i

196 Both drugs caused a dose-related inhibition of COL1A1 production and mRNA le

197 Dose-related inhibition of growth is detectable as ICS d

198 tiangiogenic activity of CEP-5214 revealed a dose-related inhibition of microvessel growth ex vivo in

199 pain, acute morphine administration produced dose-related inhibition of referred viscerosomatic hyper

200 following neuropathy, spinal IL-6 produced a dose-related inhibition of the electrically evoked C-fib

201 This study found a significant dose-related ketamine effect on scores on the Hamilton D

202 (MeHg) is highly neurotoxic with an apparent dose-related latency period between time of exposure and

203 This study demonstrates significant and dose-related LDL cholesterol lowering with a PCSK9 monoc

204 PACAP knock-outs, and was associated with a dose-related lethality absent in wild-type mice.

205 Dose-related linear increases in area under the concentr

206 Here, we demonstrated a dose-related, long-lasting increase in REM sleep followi

207 esponses of spinal dorsal horn neurones in a dose related manner.

208 5) reduced by trioxifene administration in a dose-related manner (maximal reduction, 98% from control

209 ciated with an increased risk of asthma in a dose-related manner (more than two courses of antibiotic

210 ecreased self-administration of alcohol in a dose-related manner and attenuated cue- and stress-induc

211 (2.5mg/kg) of icilin was also inhibited in a dose-related manner by clonidine pretreatment (0.03-0.15

212 ubation, prolactin release is inhibited in a dose-related manner by cortisol.

213 other agents autoregulation is impaired in a dose-related manner.

214 ity and angiotensin levels were reduced in a dose-related manner.

215 ncreased by perinatal dieldrin exposure in a dose-related manner.

216 ion against challenge with B. anthracis in a dose-related manner.

217 ic responses of patients to CpG therapy in a dose-related manner.

218 hol intoxication and hemorrhagic shock, in a dose-related manner.

219 Delta(9)-THC increased neural noise in a dose-related manner.

220 mproved with supplemental carbohydrates in a dose-related manner; the 12% carbohydrate group performe

221 ntravitreal injection of KA caused time- and dose-related MMP-9 upregulation in the retina.

222 y with a pharmacologic profile that combines dose-related monoamine modulation with phosphorylation o

223 ntrolateral medulla, also showed significant dose-related N(2)O-induced c-Fos expression.

224 Sodium oxybate was well tolerated overall; dose-related nausea (<or=28% of patients) and dizziness

225 ke WT mice, lead-treated MT-null mice showed dose-related nephromegaly.

226 6 h post MCAO provided significant (P<0.05) dose-related neuroprotection reducing infarct size by 42

227 MVA induced a dose-related neutralizing antibody and vaccinia virus-sp

228 larly, paclitaxel also produced a marked and dose-related NF-kappaB activation.

229 Robust and dose-related occupancy was also observed at 5-HT(2A) rec

230 IgG and neutralising antibody titres were dose-related (p=0.0003 for IgG ELISA and p<0.0001 for th

231 lular proton radiosensitivity using a single dose-related parameter (R (2) = 0.66).

232 Dose related pharmacokinetics with near zero order kinet

233 The most common adverse event was dose-related photosensitivity.

234 1A-31 from age 15 to 18 months resulted in a dose-related preservation of BFCN area and one month of

235 Conversion by the first bolus was dose related (range: placebo, 3.3% to 86.7% for 900 micr

236 ovoking symptoms (2.1% vs 16.1%, P = .0005), dose-related reactions requiring treatment (0.0% vs 3.8%

237 howed that MK-0364, given orally, produced a dose-related reduction in [(18)F]MK-9470 binding reflect

238 inhaled corticosteroids is associated with a dose-related reduction in bone mineral density.

239 of p120ctn using siRNA caused a dramatic and dose-related reduction in cellular levels of VE-cadherin

240 noceptor agonist noradrenaline (NA) caused a dose-related reduction in evoked excitatory postsynaptic

241 P < .05; 200 mg twice daily), and induced a dose-related reduction in ex vivo prostaglandin D2-media

242 ese studies demonstrated that CHA produces a dose-related reduction in IOP.

243 an with adenosine (P< or =0.01) because of a dose-related reduction in subjective side effects, as ob

244 A dose-related reduction in the Disease Activity Score in

245 osine receptor stimulation, accompanied by a dose-related reduction in the incidence and severity of

246 o the bathing medium (1-10 mM) resulted in a dose-related reduction of fEPSP amplitudes (up to 52% re

247 CSEE caused dose-related reductions in body weight gain (as well as

248 t (p < 0.001) mean (95% confidence interval) dose-related reductions in Lp(a) compared to control: 29

249 CSK9 with evolocumab resulted in significant dose-related reductions in Lp(a).

250 t 2.57 to 23.8 mg/kg/dose b.i.d. resulted in dose-related reductions in neovascularization in vivo in

251 Dose-related reductions in plasma HIV-1 RNA loads correl

252 There is a dose-related relationship between prednisone use and pne

253 stroke risk with antipsychotic use was in a dose-related relationship.

254 Aliskiren induced a remarkable dose-related renal vasodilation in low-sodium balance.

255 in ICARS (Bonferroni p=0.03) and suggested a dose-related response in ICARS, FARS, and ADL scores.

256 There was a dose-related response in phase 1 with a greater effect i

257 9*2 (R144C) and CYP2C9*3 (I359L) variants on dose-related response or toxicity in a randomized trial

258 rapib treatment groups with no evidence of a dose-related response.

259 r 10 mSv; 95% CI, 1.05-1.15) with a possible dose-related response.

260 Dose- related retinal toxicity could occur in pre-treate

261 tagonist, S33084 (0.04-0.63 mg/kg), caused a dose-related reversal of delay-dependent impairment in b

262 ricular rate response during induced AF in a dose-related, reversible manner without systemic side ef

263 -arterial infusion of capsaicin results in a dose-related rise in MAP and HR that is significantly re

264 ative glucocorticoid prednisolone-equivalent dose-related risks and hazard ratios (HRs) of first all-

265 efficacious for critically ill patients, the dose-related risks of IV amiodarone should be taken into

266 The primary study objective was dose-related safety and tolerability of ABI-H0731 in hea

267 EV71 vaccine was well tolerated, and no dose-related safety concerns were observed.

268 To determine the dose-related safety, immunogenicity, and protective effi

269 Flupirtine caused dose-related sedation and suppressed electroencephalogra

270 No dose-related serious AEs were observed.

271 The proteins produce a dose-related shift of diffracted intensity to the cubic

272 A dose-related significant reduction in neurites occurred

273 Longer term, dose-related studies are needed to determine the minimum

274 LSD produced dose-related subjective effects across the 3 doses (6.5,

275 Single microdoses of LSD produced orderly dose-related subjective effects in healthy volunteers.

276 SSR dose-related suppression of the nickel CHS response was

277 An apparent dose-related survival benefit warrants further study.

278 A dose-related survival difference was demonstrated in pat

279 PF-04523655 showed a dose-related tendency for improvement in BCVA in DME pat

280 Neuraxial-morphine-induced side-effects are dose related; therefore, the minimum effective dose shou

281 estion of skin surface area and UVB exposure dose, related to erythema, necessary to achieve a given

282 Patients were evaluated for dose-related toxicities, selective replication within tu

283 nd additional studies are required to reduce dose-related toxicity and improve tumor localization.

284 However, dose-related toxicity has been one of the major limiting

285 No dose-related toxicity or attributable SAEs at the 1-year

286 The treatment was well tolerated with no dose-related toxicity other than the targeted depletion

287 No dose-related toxicity was found with cooling anesthesia.

288 ely, clinical efficacy was not observed, and dose-related toxicity was seen.

289 on alpha (IFNalpha) is frequently limited by dose-related toxicity.

290 ease in the dose is not possible, because of dose-related toxicity.

291 cy of chemotherapeutic agents while reducing dose-related toxicity.

292 nia (32%), and neutropenia (24%), as well as dose-related, transient QTc prolongation (17%).

293 17%, respectively; P=0.63), and there was no dose-related trend (P=0.80).

294 ition of VEGF to BHK cells caused a time and dose-related upregulation of approximately 57-kDa zymoge

295 Among B cells remaining in blood, we found a dose-related upregulation of costimulatory molecules aft

296 ino-1-methyl-6-phenylimidazo[4,5-b]pyridine: dose-related variation in the joint effects of common di

297 icilin (0.5, 1, 2.5, 5mg/kg, i.p.) displayed dose-related WDS that were inhibited by pretreatment wit

298 transferase and alanine aminotransferase and dose-related weight loss.

299 Retention in treatment was dose related, with 39%, 60%, and 68% of patients in the

300 Dose-related worsening of glycemic control was noted in